Drug intelligence / Profile preview

TG20

Development stage: Preclinical
Lead developer: TG Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TG20 is an anti-CD20 monoclonal antibody co-developed by GTC Biotherapeutics and LFB Biotechnologies. It is uniquely produced in the milk of transgenic goats, leveraging GTC's production platform and LFB's antibody engineering expertise. The drug is being developed for the treatment of cancer and autoimmune diseases, aiming to improve upon the clinical profile of rituximab by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on TG20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG20.

Explore the full profile